ArticleMolecular neurobiology2025
RNF213 Knockdown and Inflammation Promote Angiogenesis and Phenotype Switching by JAK2/STAT3 Pathway in Moyamoya Disease.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An Rnf213-deficient hypoperfusion model reveals Moyamoya-relevant neurovascular remodeling.Angiogenesis · 2026Article
- Molecular and multimodal biomarkers in Moyamoya disease: from pathogenic mechanisms to clinical translation.European journal of medical research · 2026Review
- Glioblastoma pathophysiology: roles of aging driven changes in STAT3 interactions with NF-κB dimer components in the modulation of the mitochondrial melatonergic pathway and night-time inflammation resolution.Exploration of targeted anti-tumor therapy · 2026Review
- MicroRNA-29b-3p promotes endothelial cell inflammation via NTRK2/PI3K/NLRP3 pathway in Moyamoya disease.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease. Ring finger protein 213 (RNF213) is a susceptibility gene for MMD. Numerous studies have highlighted that RNF213 regulates angiogenesis; its precise regulatory role and mechanism remain controversial. Moreover, the impacts and mechanisms of RNF213 on vascular smooth muscle cell (VSMC) phenotype switching are also rarely reported. Inflammation is an important factor in promoting the occurrence and development of MMD, necessitating further investigations to clarify its specific role. In vitro experiments, human brain microvascular endothelial cells (HBMECs), and human aortic smooth muscle cells (HASMCs) were used. RNF213 function was suppressed using small interfering RNA, while inflammatory stimulation was induced by lipopolysaccharide (LPS). We found that knockdown of RNF213 could promote HBMEC proliferation, migration, and angiogenesis and inhibit apoptosis in HBMECs. Moreover, these effects were enhanced by treating with LPS. Bioinformatics analysis revealed protein interactions between RNF213 and JAK2/STAT3. Subsequent validation demonstrated that loss of RNF213 function and LPS could upregulate the expression of JAK2, STAT3, and VEGF in HBMECs. Inhibition of the JAK2/STAT3 signaling pathway effectively reversed the increase in VEGF expression induced by RNF213 dysfunction. Furthermore, RNF213 dysfunction and LPS treatment could promote the proliferation, migration, and phenotype switching and inhibit apoptosis in HASMCs. Activation of the JAK2/STAT3 signaling pathway appeared to facilitate the phenotype switching of HASMCs. Impairment of RNF213 function was found to promote angiogenesis and phenotype switching in MMD, with these effects being enhanced under inflammatory conditions, potentially mediated by the activation of the JAK2/STAT3 signaling pathway.
Indexed as
Identifiers
40467938What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.